BI 409306: all 22 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by KetamineCompletedNCT04602221Phase 1Results posted
• This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)CompletedNCT03934203Phase 1Results posted
• This Study in Healthy Men and Women Tests How the Body Takes up BI 409306CompletedNCT03505151Phase 1Results posted
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsTerminatedNCT03351244Phase 2Results posted
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 YearTerminatedNCT03230097Phase 2Results posted
• This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each OtherCompletedNCT03193307Phase 1Results posted
• Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy VolunteersCompletedNCT03151499Phase 1Results posted
• Influence of Fluvoxamine on the Pharmacokinetics of BI 409306CompletedNCT02853136Phase 1Results posted
• Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female SubjectsCompletedNCT02635750Phase 1Results posted
• BI 409306 Cardiac Safety Trial in Healthy VolunteersCompletedNCT02438683Phase 1Results posted
• Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy VolunteersCompletedNCT02392468Phase 1Results posted
• BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.CompletedNCT02337907Phase 2Results posted
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.CompletedNCT02281773Phase 2Results posted
• Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor MetabolizersCompletedNCT02248259Phase 1Results posted
• Alzheimer Disease Proof of Concept Study With BI 409306 Versus PlaceboCompletedNCT02240693Phase 2Results posted
• Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy VolunteersCompletedNCT02222168Phase 1Results posted
• Safety and Tolerability of BI 409306 in Patients With SchizophreniaCompletedNCT01892384Phase 1Results posted
• Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male VolunteersCompletedNCT01841112Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306CompletedNCT01611311Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising DosesCompletedNCT01505894Phase 1Results posted
• Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male VolunteersCompletedNCT01493570Phase 1Results posted
• Safety Tolerability and Pharmacokinetic of BI 409306CompletedNCT01343706Phase 1Results posted

← BI 409306 overview